Wyeth Will Pursue Maintenance Indication For Bifeprunox; Acute Treatment Is Unclear
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s “not approvable” decision for both claims could set the antipsychotic’s potential approval timeframe back two years.